Head and neck squamous cell carcinoma (HNSCC) develops in the epithelial lining of the oral cavity, hypopharynx, oropharynx or larynx. The standard treatment includes platinum-based and taxane-based chemotherapy that causes both drug resistance and negative side effects.For that reason, there is a need to explore new low-toxicity options for HNSCC treatment.
Researchers from the Brigham and Women’s Hospital and Harvard Medical School and collaborators recently conducted a study investigating the regulation of immune checkpoint molecules in cancer. Analyzing data from The Cancer Genome Atlas pan-cancer cohort (over 10,000 patients and 11,000 samples across 34 different cancer subtypes), they found that high expression of the immune checkpoint B7-H3 (CD276) and high mTORC1 activity correlate with immunosuppressive phenotypes and worse clinical outcomes.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified sulfonamide derivatives acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
RSS
